Loading...
Market
What will be Wave Life Sciences' next strategic focus area by June 30, 2025?
2
Resolution / Starting Odds
Neurological Disorders • 25%
Genetic Diseases • 25%
Oncology • 25%
Other • 25%
Official press releases from Wave Life Sciences
Story
Takeda Ends Six-Year $260M Collaboration with Wave Life Sciences on Mutant Huntingtin-Specific ASO
Oct 16, 2024, 08:55 AM
Takeda Pharmaceutical Company, a Japanese pharma, has decided to terminate its option for the mutant huntingtin-specific ASO target in its collaboration with Wave Life Sciences. This decision marks the end of a six-year partnership into which Takeda had invested $260 million. The collaboration was focused on developing treatments for Huntington's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Phase 3 trial initiation • 25%
FDA breakthrough therapy designation • 25%
Partnership with a major pharma • 25%
Other milestone • 25%
Announces new clinical trial • 25%
Announces new partnership • 25%
Announces new funding • 25%
No significant announcements • 25%
New clinical trial phase announced • 25%
New therapeutic indication announced • 25%
No major announcements • 25%
Other significant announcements • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%